Test ID: NMDCS
NMDA-Receptor Antibody by CBA, Serum
Secondary ID 
A test code used for billing and in test definitions created prior to November 2011
61516
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Yes
Useful For Suggests clinical disorders or settings where the test may be helpful
Evaluating new onset encephalopathy (noninfectious or metabolic) comprising 1 or more of the following: confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, seizures, or hypoventilation
Evaluating limbic encephalitis
Directing a focused search for cancer
Investigating encephalopathy appearing in the course or wake of cancer therapy, and not explainable by metastasis or drug effect
Method Name A short description of the method used to perform the test
Cell-binding assay (CBA) detects IgG specific for NMDA-R (N-Methyl-D-aspartate receptor) by indirect immunofluorescence (IFA)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
NMDA-R Ab CBA, Serum
Aliases Lists additional common names for a test, as an aid in searching
Anti-NMDA
N-Methyl D-Aspartate Ab
NMDA Receptor Ab
N-Methyl D-Aspartate Ab
NMDA Receptor Ab
External
link
PDF
document
Excel
document
Word
document